

Mydayis[®] (mixed-salts of a single-entity amphetamine product) – First-time generic

- On October 10, 2023, [Teva launched](#) an [AB-rated](#) generic version of Takeda's [Mydayis \(mixed-salts of a single-entity amphetamine product\)](#) extended-release capsules.
 - Mydayis is a schedule II controlled substance.
 - [SpecGX](#) and [Sun](#) received FDA approval of AB-rated generic versions of Mydayis on August 31, 2023 and September 27, 2023, respectively. Launch plans are pending.
- Mydayis is approved for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 13 years and older.
- Other combination mixed salts amphetamine products are available: brand and generic [Adderall[®]](#) tablets and brand and generic [Adderall XR[®]](#) capsules.
 - Adderall and Adderall XR are both indicated for ADHD; Adderall is also approved for narcolepsy.
- Mydayis carries a boxed warning for abuse and dependence.